SCHEMBL1497028

SCHEMBL1497028

CC(C)(C)OC(=O)Nc1cscc1NC(=O)c1ccc(CN(CCCN2CCCC2)C(=O)NC2CCCC2)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.38
USP2 O75604 4/20 0.38
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 1/20 0.38
ALOX15 P16050 1/20 0.38
KMT2A Q03164 1/20 0.38
HPGD P15428 2/20 0.38
MLNR O43193 1/20 0.38
HRH3 Q9Y5N1 3/20 0.36
SLC2A1 P11166 1/20 0.36
TSHR P16473 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HSD17B10 Q99714 2/20 0.36
GAA P10253 2/20 0.36
ACHE P22303 1/20 0.36
BACE1 P56817 1/20 0.36
BMPR1B O00238 1/20 0.36
BMPR1A P36894 1/20 0.36
TGFBR1 P36897 1/20 0.36
ACVRL1 P37023 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1497087 0.96 SLC2A1 (0.41) KDM4EUSP2ALDH1A1MEN1ALOX15
SCHEMBL1496882 0.95 KDM4E (0.42) KDM4EUSP2ALDH1A1MEN1ALOX15
SCHEMBL1496845 0.94 KDM4E (0.45) KDM4EUSP2ALDH1A1MEN1KMT2A
SCHEMBL1497078 0.94 ALDH1A1 (0.46) KDM4EUSP2ALDH1A1MEN1KMT2A
SCHEMBL1497145 0.92 KDM4E (0.43) KDM4EUSP2ALDH1A1MEN1KMT2A
SCHEMBL1496831 0.91 KDM4E (0.38) KDM4EUSP2ALDH1A1MEN1ALOX15
SCHEMBL1497149 0.90 KDM4E (0.41) KDM4EUSP2ALDH1A1MEN1ALOX15
SCHEMBL1497154 0.89 GAA (0.47) KDM4EUSP2ALDH1A1MEN1ALOX15
SCHEMBL12831881 0.89 KDM4E (0.39) KDM4EUSP2ALDH1A1MEN1ALOX15
SCHEMBL3230728 0.88 KDM4E (0.46) KDM4EUSP2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288380-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-10-16 US disclosed
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
EP-2292611-B1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2012-07-25 EP disclosed
US-8198271-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-06-12 US disclosed
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-31 US disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed
WO-2009142321-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE 参天製薬株式会社 (JP) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE CBR1, NAT1, PRMT1 KDM4E 2885/4885USP2 598/4885ALDH1A1 1240/4885
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE HNMT, HRH4, CHRM1 KDM4E 2194/4885USP2 702/4885ALDH1A1 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.